Collplant biotechnologies announces patent granted in u.s. for photocurable dermal filler

-  intellectual property rights secured in one of the largest target markets for collplant's potential products - rehovot, israel , nov. 1, 2023 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that the u.s. patent and trademark office has granted a patent that covers collplant's photocurable dermal filler product candidate, being developed for the aesthetics market. u.s. patent no.
CLGN Ratings Summary
CLGN Quant Ranking